Susanna Naggie

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes
    Susanna Naggie
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Infect Dis 205:376-83. 2012
  2. doi request reprint Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    J Antimicrob Chemother 65:2063-9. 2010
  3. doi request reprint A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors
    Susanna Naggie
    Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
    Am J Med 124:276.e1-7. 2011
  4. pmc Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 56:444-54. 2012
  5. pmc Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
    Alexander J Thompson
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27701, USA
    J Hepatol 56:313-9. 2012
  6. pmc Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 53:389-95. 2011
  7. pmc Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study
    Neela D Goswami
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 7:e46029. 2012
  8. pmc The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
    Paul J Clark
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    Dig Dis Sci 57:2213-21. 2012
  9. pmc Management of hepatitis C virus infection: the basics
    Susanna Naggie
    Duke University School of Medicine, Durham, NC, USA
    Top Antivir Med 20:154-61. 2012
  10. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Gastroenterology 139:1181-9. 2010

Collaborators

Detail Information

Publications22

  1. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes
    Susanna Naggie
    Duke Clinical Research Institute, Durham, North Carolina, USA
    J Infect Dis 205:376-83. 2012
    ..We investigate these polymorphisms in a cohort of human immunodeficiency virus (HIV)/HCV-coinfected patients...
  2. doi request reprint Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    J Antimicrob Chemother 65:2063-9. 2010
    ..Here, we summarize the current information regarding the effectiveness of protease inhibitors in treating chronic HCV and discuss the key challenges now facing the field...
  3. doi request reprint A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors
    Susanna Naggie
    Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
    Am J Med 124:276.e1-7. 2011
    ..The epidemiology of community-associated Clostridium difficile infection is not well known. We performed a multicenter, case-control study to further describe community-associated C. difficile infection and assess novel risk factors...
  4. pmc Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response
    Susanna Naggie
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 56:444-54. 2012
    ..004). Induction of innate immunity genes was also lower in unfavorable genotypes. ISG expression at baseline and induction with IFN was independent of IL28B genotype...
  5. pmc Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
    Alexander J Thompson
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27701, USA
    J Hepatol 56:313-9. 2012
    ..We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related thrombocytopenia, neutropenia, and leukopenia...
  6. pmc Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, NC, USA
    Hepatology 53:389-95. 2011
    ..25, 95% confidence interval = 0.08-0.84, P = 0.025) but not with the rate of RBV dose modification (required per protocol at Hb < 9.5 g/dL). There was no association between the ITPA variants and SVR...
  7. pmc Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study
    Neela D Goswami
    Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 7:e46029. 2012
    ..To determine the feasibility and case detection rate of a geographic information systems (GIS)-based integrated community screening strategy for tuberculosis, syphilis, and human immunodeficiency virus (HIV)...
  8. pmc The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection
    Paul J Clark
    Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC 27715, USA
    Dig Dis Sci 57:2213-21. 2012
    ..Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined...
  9. pmc Management of hepatitis C virus infection: the basics
    Susanna Naggie
    Duke University School of Medicine, Durham, NC, USA
    Top Antivir Med 20:154-61. 2012
    ..This article summarizes a basic review presented by Susanna Naggie, MD, at the IAS-USA live management of HCV continuing medical education program held in Atlanta in October ..
  10. pmc Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Gastroenterology 139:1181-9. 2010
    ..We aimed to replicate this finding in an independent cohort from the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C and to investigate the effects of these variants beyond week 4...
  11. pmc Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection
    Brianna L Norton
    Duke University Medical Center, Durham, North Carolina 22710, USA
    AIDS Patient Care STDS 26:541-5. 2012
    ..This increase was not solely due to liver related events. Instead, comorbidities such as diabetes, renal disease, and psychiatric/substance abuse played a larger role in the health-care utilization in the HIV/HCV coinfected population...
  12. pmc Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals
    Susanna Naggie
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Gastroenterology 142:1324-1334.e3. 2012
    ..We review the latest developments and obstacles to treating coinfected patients...
  13. pmc Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014
    Cody A Chastain
    Division of Infectious Diseases, Vanderbilt University Medical Center, A 2200 MCN, 1161 21st Avenue, Nashville, TN, 37232 2582, USA
    Curr HIV/AIDS Rep 10:408-19. 2013
    ..The management of adverse effects of HCV therapy and treatment considerations in patients with cirrhosis are also reviewed. ..
  14. pmc Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States
    Anna K Person
    Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    AIDS Patient Care STDS 24:539-43. 2010
    ..HIV testing was also widely accepted. Pairing QFT with opt-out HIV testing should be strongly considered when possible...
  15. doi request reprint Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis
    Susanna Naggie
    Division of Infectious Diseases, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Chest Med 30:337-53, vii-viii. 2009
    ....
  16. doi request reprint Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options
    Susanna Naggie
    Division of Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA
    J Antimicrob Chemother 65:1094-9. 2010
    ..Here, we discuss the current recommendations and recent guidelines, and the evidence available for various PI-based ART regimens in treatment-naive patients. We also discuss adverse effects and the use of PIs in special circumstances...
  17. pmc Community-based HCV screening: knowledge and attitudes in a high risk urban population
    Brianna L Norton
    Division of Infectious Diseases and International Health, Duke University Medical Center, Box 102358, Durham, NC 27710, USA
    BMC Infect Dis 14:74. 2014
    ..Community-based screening may be one strategy in which to reach such persons; however, the acceptance of HCV testing, when many high-risk individuals may not have access to HCV specific medications, remains unknown...
  18. doi request reprint Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline
    Norma I Rallon
    Hospital Carlos III, Madrid, Spain bDuke Clinical Research Institute, Durham, North Carolina, USA
    AIDS 25:269-71. 2011
    ..No protective role of IL28B polymorphism was found examining both HIV-disease progression and HIV-protection...
  19. pmc Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?
    Andrew J Muir
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina Division of Gastroenterology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina Electronic address
    Clin Gastroenterol Hepatol 13:2166-72. 2015
    ..This review will discuss the strategies that will be necessary to realize this opportunity to cure all persons with HCV infection. ..
  20. pmc An integrated alcohol abuse and medical treatment model for patients with hepatitis C
    Rae Jean Proeschold-Bell
    Duke Global Health Institute, Center for Health Policy and Inequalities Research, Duke University, 2812 Erwin Rd, 403, Durham, NC 27705, USA
    Dig Dis Sci 57:1083-91. 2012
    ..Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment...
  21. pmc Feasibility and willingness-to-pay for integrated community-based tuberculosis testing
    Neela D Goswami
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    BMC Infect Dis 11:305. 2011
    ..Community-based screening for TB, combined with HIV and syphilis testing, faces a number of barriers. One significant barrier is the value that target communities place on such screening...
  22. ncbi request reprint Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population
    Susan C Morpeth
    Duke University Medical Center, Durham, North Carolina, 27710, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
    AIDS Res Hum Retroviruses 23:1230-6. 2007
    ....